Have a feature idea you'd love to see implemented?
Let us know!
APVO Aptevo Therapeutics Inc
Price (delayed)
$4.41
Market cap
$2.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$675.62
Enterprise value
-$716,558
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603,
Highlights
APVO's EPS has surged by 82% year-on-year and by 54% since the previous quarter
The company's debt fell by 13% YoY and by 3.9% QoQ
APVO's net income is down by 47% YoY but it is up by 4.9% QoQ
Aptevo Therapeutics's equity has shrunk by 70% YoY
The quick ratio has plunged by 53% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of APVO
Market
Valuations
Earnings
Shares outstanding
500,327
Market cap
$2.21M
Enterprise value
-$716,558
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$23.72M
EBIT
-$23.72M
EBITDA
-$23.32M
Free cash flow
-$23.28M
Per share
Balance sheet
Liquidity
EPS
-$675.62
EPS diluted
-$675.62
Free cash flow per share
-$81.65
Book value per share
$17.36
Revenue per share
$0
TBVPS
$53.13
Total assets
$15.15M
Total liabilities
$10.73M
Debt
$4.83M
Equity
$4.42M
Working capital
$4.13M
Debt to equity
1.09
Current ratio
1.7
Quick ratio
1.32
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-130.8%
Return on equity
-348.7%
Return on invested capital
-376.4%
Return on capital employed
-256.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APVO stock price
How has the Aptevo Therapeutics stock price performed over time
Intraday
-2.65%
1 week
7.82%
1 month
-58.9%
1 year
-98.54%
YTD
-98.5%
QTD
-33.68%
Financial performance
How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.6M
Net income
-$23.72M
Gross margin
N/A
Net margin
N/A
APVO's net income is down by 47% YoY but it is up by 4.9% QoQ
The company's operating income rose by 18% YoY and by 5% QoQ
Growth
What is Aptevo Therapeutics's growth rate over time
Valuation
What is Aptevo Therapeutics stock price valuation
P/E
N/A
P/B
0.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has surged by 82% year-on-year and by 54% since the previous quarter
APVO's P/B is 95% below its 5-year quarterly average of 5.0 and 17% below its last 4 quarters average of 0.3
Aptevo Therapeutics's equity has shrunk by 70% YoY
Efficiency
How efficient is Aptevo Therapeutics business performance
Aptevo Therapeutics's ROA has plunged by 153% YoY and by 11% from the previous quarter
The company's return on invested capital has shrunk by 108% YoY but it rose by 3.4% QoQ
The return on equity has declined by 31% since the previous quarter
Dividends
What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APVO.
Financial health
How did Aptevo Therapeutics financials performed over time
APVO's total assets is 41% higher than its total liabilities
The quick ratio has plunged by 53% YoY and by 11% from the previous quarter
The company's current ratio fell by 45% YoY and by 4% QoQ
The company's debt is 9% higher than its equity
The debt to equity has soared by 187% YoY but it fell by 3.5% QoQ
Aptevo Therapeutics's equity has shrunk by 70% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.